DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Tuesday, October 9, 2007

Akesis Pharmaceuticals , IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes

Oct 8, 2007 - - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced that it has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead product candidate AKP-020, a novel vanadium compound that is expected to show considerable potential as a treatment for patients with Type 2 Diabetes... Akesis' Press Release -

Alimera Sciences and pSivida , Pivotal Phase 3 Trial of Medidur™ FA for Diabetic Macular Edema

October 08, 2007 - Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI), announced that enrollment is complete for the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur™ FA for the treatment of Diabetic Macular Edema...
Alimera Sciences' Press Release - pSivida's Press release -

Saturday, October 6, 2007

MyCareTeam, New Diabetes Tool Available on ADA Web Site

October 4, 2007– The American Diabetes Association unveiled a new web-based diabetes tool that makes it easier for people with diabetes – and their care providers – to share and organize important health information to improve their diabetes care. The tool, My Diabetes Connector, is a diabetes management software application developed by
a software and services company, MyCareTeam, Inc...
ADA's Press Realease on MyCareTeam [PDF] -

VERICHIP and DIGITAL ANGEL, IMPLANTABLE RFID GLUCOSE-SENSING MICROCHIP

September 24, 2007 - VeriChip Corporation (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, and Digital Angel Corporation (AMEX: DOC), owner of Patent No. 7,125,382 for an embedded bio-sensor system, announced they have entered into a memorandum of understanding with RECEPTORS LLC, an expert in the field of proteomics and the development of artificial receptors to develop a prototype renewable glucose sensor to use in conjunction with an implantable bio-sensing RFID microchip to measure glucose levels in the human body. VeriChip will manage the partnership project, with the assistance of Digital Angel, aimed at accelerating the development of an embedded glucose bio-sensing system for humans. RECEPTORS will be responsible for demonstrating a self-contained glucose-sensing system in Phase I of the project...
VeriChip's Press Release - Digital Angel's press Release - RECEPTORS' Press release [PDF] -

HMM , Blood Glucose Meter for Self-Monitoring With Bluetooth Technology

the First CE-Certified and EU-Registered Blood Glucose Meter for Self-Monitoring With Bluetooth Technology on the Market :

October 4, 2007 - HMM Heidelberger-Medical-Marketing GmbH - Always One Step Ahead.
"Finally - our smartLABgenie is available on the market. Initiator of this product introduction was the desire of many patients for a compact, easy-to-use and at the same time modern tool to smoothly and easily control every day influences on diabetics. The huge advantage: The Bluetooth option renders it possible to integrate our smartLABgenie in every telemedicine system, as well as to transfer data via cell phone and PC..."... HMM's Press Release -

Friday, October 5, 2007

Home Diagnostics on Microsoft HealthVault

Thursday October 4, 2007 - Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced its TRUEtrack® and TRUEread™ blood glucose meters will operate on Microsoft HealthVault, a newly launched consumer health platform. The integrated system will enable TRUEtrack and TRUEread users to download data directly from the meter to the online platform, providing the ability to collect, organize and share diabetes management information in a privacy- and security-enhanced setting... Home Diagnostics' Press Release -

Wednesday, October 3, 2007

Phylonix Phase II SBIR to Develop Zebrafish Models for Eye Diseases

October 2, 2007- Phylonix Pharmaceuticals, Inc. announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for "New Models for Eye Diseases" will support the Phylonix program over a period of three years... Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world... Phylonix Pharmaceuticals' Press Release -

CardioVascular BioTherapeutics, Phase I Wound Healing Trial

Oct. 2, 2007--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company's protein-based drug candidate (CVBT-141B), formulated with human fibroblast growth factor -1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers. FGF-1 was applied topically in 8 subjects at a single site and was found to be well tolerated... CardioVascular BioTherapeutics' Press Release -

Generex Biotechnology, new United States Patent

Mass., Oct. 2, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that the United States Patent and Trademark Office has granted the Company a new United States Patent.
The patent, titled ``Metered Dose Spray Device for Use with Macromolecular Pharmaceutical Agents such as Insulin,''... Generex Biotechnology's Press Release -

Tuesday, October 2, 2007

DiaMedica, phase II results for DM-71 in type 2 diabetes trial

October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes... DiaMedica's Press Release -

Novartis, Galvus European approval as new treatment for type 2 diabetes

September 28, 2007 - Galvus (vildagliptin), a new once-daily oral treatment for patients with type 2 diabetes, has been granted European Union approval. Galvus is the only drug in its class to offer such a broad range of indications for use in combination therapies with other anti-diabetic medicines... Novartis' Press Release -